Clinical trials: Insulin
Diabetes Mellitus, Type 1
GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)
The objectives of the main study is to: Evaluate the safety of giving GAD-Alum (Glutamic acid decarboxylase) (Diamyd) directly into lymph glands in combination with an oral vitamin D regimen Evaluate how the above mentioned…
- Trial name
- DIAGNODE (NCT02352974)
- Testing
- GAD-Alum, Vitamin D
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Johnny Ludvigsson
Diabetes Mellitus, Non-Insulin-Dependent
MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)
The phase III clinical trial examines the efficacy, safety, and tolerability of the addition of MK0431/ONO-5435 to Japanese patients with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on diet/exercise…
- Trial name
- NCT00837577
- Testing
- Sitagliptin, Voglibose
- Volunteers
- 133 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Cancer
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
This is an open-label, Phase 1/2 study to evaluate the safety of durvalumab (MEDI4736) in combination with oxaliplatin/capecitabine chemotherapy in metastatic/locally advanced oesophageal cancer (OC) and with neoadjuvant…
- Trial name
- NCT02735239
- Testing
- Durvalumab, Tremelimumab, Oxaliplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 73 people
- Sponsor
- Ludwig Institute for Cancer Research
Type 2 Diabetes Mellitus
Insulin Glargine at Bedtime or in AM Versus NPH
To compare the efficacy and safety of once-nightly insulin glargine versus a single morning injection of glargine or once-nightly NPH insulin in ethnic minority type 2 diabetic patients inadequately controlled on combination oral…
- Trial name
- NCT00686712
- Testing
- 1- Insulin glargine QHS, 2 - Insulin glargine QAM, 3 - NPH insulin QHS
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Charles Drew University of Medicine and Science
Type 2 Diabetes Mellitus
Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes
This study in Germany is designed to compare the effects of twice-daily exenatide plus metformin and twice-daily premixed human insulin aspart plus metformin with respect to glycemic control, as measured by HbA1c, combined with…
- Trial name
- NCT00434954
- Testing
- exenatide twice daily (BID), premixed insulin aspart twice daily (BID)
- Where
- 39 sites in Germany
- Volunteers
- 494 people
- Sponsor
- AstraZeneca
HIV Infections, Cardiovascular Disease
Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome
We hypothesize that the hearts of HIV+ people with The Metabolic Syndrome use and oxidize fats and sugars inappropriately, and that this may impair the heart's ability to pump blood.
- Conditions
- HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy
- Trial name
- WU197 (NCT00656851)
- Testing
- Pioglitazone, Exercise Training
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes
This trial is conducted in Africa, Europe, North and South America and Oceania. The aim of this trial is to compare the effect and safety on blood glucose control in pregnant women with type 1 diabetes of a modern insulin…
- Trial name
- NCT00474045
- Testing
- insulin detemir, NPH insulin, insulin aspart
- Where
- 98 sites in Argentina, Australia and 15 more
- Volunteers
- 470 people
- Sponsor
- Novo Nordisk A/S
Diabetes
Mechanisms of Glucose Lowering Effect of Colesevelam HCl
The mechanism by which colesevelam HCl lowers glucose is not known. Knowledge of the potential mechanism of action is important for defining the role of the drug among oral antidiabetic agents available for use in subjects with…
- Trial name
- NCT00596427
- Testing
- Colesevelam HCL
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Carine Beysen
Insulin Sensitivity
Insulin Sensitivity and Beta Cell Function After Carbohydrate Loading in Hip Replacement Surgery
The purpose of this study is to determine whether preload of carbohydrate or water before elective hip replacement improve insulin sensitivity and or beta cell function in human.
- Trial name
- NCT01774084
- Testing
- Experimental: PreOp, NutriciaNordica AB
- Where
- 2 sites in Sweden
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study
The investigators are conducting this research to study the effect of Liraglutide on blood pressure. Several studies have shown increased cardiovascular complications and deaths in diabetics with hypertension.
- Trial name
- NCT02299388
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Tulane University School of Medicine
Type 2 Diabetes Mellitus
Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin
This study will evaluate whether bile acids are able to increase insulin sensitivity and enhance glycemic control in T2DM patients, as well as exploring the mechanisms that enhance glycemic control.
- Trial name
- NCT02033876
- Testing
- Ursodiol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without metformin over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-L (NCT00715624)
- Testing
- Lixisenatide (AVE0010), Basal Insulin, Metformin
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 496 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus, Obese
Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus
To study the effect of an ileocolonic formulation of ox bile extract on insulin sensitivity, postprandial glycemia and incretin levels, gastric emptying, body weight and fasting serum FGF-19 (fibroblast growth factor) levels in…
- Conditions
- Type 2 Diabetes Mellitus, Obese, Overweight
- Trial name
- NCT02871882
- Testing
- Gastric Emptying test, Mixed Oral Glucose Tolerance test, Conjugated bile acids sodium
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Mayo Clinic
Metabolic Syndrome X
Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity
The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult population suffers the disease. Banaba has shown evidence that has on metabolic syndrome, insulin sensitivity and insulin secretion.
- Trial name
- NCT02767869
- Testing
- Banaba
- Where
- Mexico
- Volunteers
- 24 people
- Sponsor
- University of Guadalajara
Diabetes Mellitus Type 1
A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas
This study will test the hypothesis that a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults with type 1 diabetes.
- Trial name
- NCT02092220
- Testing
- Bionic Pancreas, Insulin pump with or without CGM
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes
Two Way Crossover Closed Loop Study R-AP vs MPC
An artificial pancreas (AP) is a control system for automatic insulin delivery. The investigators have implemented a missed meal bolus detection algorithm for use within an AP control system.
- Trial name
- NCT05083559
- Testing
- MPC AP algorithm, Robust R-AP algorithm
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Oregon Health and Science University
Coronary Heart Disease, Stroke
Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes
To investigate long-term effects on cardiovascular mortality/morbidity and renal failure in type 1 diabetes patients former randomized to intensive insulin treatment
- Conditions
- Coronary Heart Disease, Stroke, Renal Failure
- Trial name
- SDIS (NCT02138006)
- Testing
- Intensive insulin treatment, Standard insulin treatment
- Where
- Sweden
- Volunteers
- 102 people
- Sponsor
- Karolinska Institutet
Type 1 Diabetes
Context Aware Data Gathering Study
Automated Insulin Delivery (AID) systems have now become an important standard-of-care for people with T1D and have demonstrated a reduction, but not elimination, of hypoglycemia during long-term studies.
- Trial name
- NCT04154904
- Testing
- Exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oregon Health and Science University
Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
Telephone Delivered Behavioral Skills Intervention for Blacks With T2DM
Blacks or African Americans have greater risk of and are more likely to die from type 2 diabetes (T2DM). Major barriers to effective diabetes care for Blacks include poor diabetes knowledge, self-management skills, empowerment…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Noninsulin Dependent
- Trial name
- DM-TBSI (NCT00929838)
- Testing
- Diabetes Knowledge/Information, Motivation/Behavioral Skills, Combined Intervention
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- State University of New York at Buffalo
Type 1 Diabetes Mellitus
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by…
- Trial name
- NCT01925989
- Testing
- LY2605541, Insulin Glargine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.